Faheem Hasnain - 09 Dec 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Director
Signature
/s/ Teresa Bair, Attorney-in-fact for Faheem Hasnain
Issuer symbol
KURA
Transactions as of
09 Dec 2025
Transactions value $
-$78,564
Form type
4
Filing time
10 Dec 2025, 16:05:03 UTC
Previous filing
02 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hasnain Faheem Director C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO /s/ Teresa Bair, Attorney-in-fact for Faheem Hasnain 10 Dec 2025 0001352620

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Options Exercise $31.2K +10K +41.7% $3.12 34K 09 Dec 2025 Direct F1
transaction KURA Common Stock Sale -$110K -10K -29.43% $10.98 24K 09 Dec 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $10.60 to $11.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.